(Q42947141)

English

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance

scientific article published on 16 November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance (English)

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

multiple drug resistance

1 reference

based on heuristic

inferred from title

Pseudomonas aeruginosa

object named as

Pseudomonas aeruginosa

1 reference

based on heuristic

inferred from title

David P Nicolau

3

object named as

David P Nicolau

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

author name string

Catharine C Bulik

1

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Henry Christensen

2

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

language of work or name

0 references

publication date

16 November 2009

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

54

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

1

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

557-559

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

27 May 2018

The current state of multidrug-resistant gram-negative bacilli in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

27 May 2018

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

27 May 2018

Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

27 May 2018

In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

16 August 2018

Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

16 August 2018

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

16 August 2018

Extended-spectrum cephalosporinases in Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

16 August 2018

Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

16 August 2018

Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

16 August 2018

Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798502

16 August 2018

Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917762

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.00912-09

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42947141&oldid=2144418230"